published meta-analysis   sensitivity analysis   studies

placebo in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsReis (Hydroxychloroquine) (TOGETHER), 2021 (REV) 3.80 [0.17; 84.65] 3.80[0.17; 84.65]Reis (Hydroxychloroquine) (TOGETHER), 2021 (REV)10%441NAnot evaluable hospitalizationdetailed resultsReis (Hydroxychloroquine) (TOGETHER), 2021 (REV) 1.32 [0.53; 3.29] 1.32[0.53; 3.29]Reis (Hydroxychloroquine) (TOGETHER), 2021 (REV)10%441NAnot evaluable viral clearance detailed resultsReis (Hydroxychloroquine) (TOGETHER), 2021 (REV) 1.09 [0.97; 1.21] 1.09[0.97; 1.21]Reis (Hydroxychloroquine) (TOGETHER), 2021 (REV)10%380NAnot evaluable viral clearance by day 14detailed resultsReis (Hydroxychloroquine) (TOGETHER), 2021 (REV) 1.09 [0.97; 1.21] 1.09[0.97; 1.21]Reis (Hydroxychloroquine) (TOGETHER), 2021 (REV)10%380NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-22 14:12 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 650 - roots T: 650